WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 遺伝性低リン血症性くる病と腫瘍誘発性骨軟化症 hereditary hypophosphatemic rickets and tumor induced osteomalacia
2. 傍神経節腫：疫学、臨床症状、診断、および組織学的検査 paragangliomas epidemiology clinical presentation diagnosis and histology
3. 遺伝性腎癌症候群 hereditary kidney cancer syndromes
4. 卵巣癌、卵管癌、および腹膜癌：病期分類および初期外科的マネージメント cancer of the ovary fallopian tube and peritoneum staging and initial surgical management
5. 小児および思春期における良性骨腫瘍：概要 benign bone tumors in children and adolescents an overview

MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.

Tanic M1, Yanowski K, Gómez-López G, Socorro Rodriguez-Pinilla M, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B, Benítez J.
International journal of cancer. Journal international du cancer.Int J Cancer.2015 Feb 15;136(3):593-602. doi: 10.1002/ijc.29021. Epub 2014 Jun 19.
Screening for germline mutations in breast cancer-associated genes BRCA1 and BRCA2 is indicated for patients with breast cancer from high-risk breast cancer families and influences both treatment options and clinical management. However, only 25% of selected patients test positive for BRCA1/2 mutati
PMID 24917463

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Smith MA1, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.
Pediatric blood & cancer.Pediatr Blood Cancer.2015 Jan;62(1):91-98. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.
BACKGROUND: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks.PROCEDURE: B
PMID 25263539

Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.

Saadatmand S1, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).
International journal of cancer. Journal international du cancer.Int J Cancer.2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.
Annual MRI and mammography is recommended for BRCA1/2 mutation carriers to reduce breast cancer mortality. Less intensive screening is advised ≥60 years, although effectiveness is unknown. We identified BRCA1/2 mutation carriers without bilateral mastectomy before age 60 to determine for whom scre
PMID 24789418

菅原宏文,福岡健吾,成田知宏,大里雅之,水野豊,岡本道孝,矢嶋信久
日本臨床外科学会雑誌 76(2), 286-291, 2015
… Gastrointestinal stromal tumor（以下，GIST）はvon Recklinghausen病や遺伝性病変以外の散発性GISTの多発例はまれである．われわれは，胃GIST術後9年目に切除した十二指腸GISTの1例を経験したので報告する．症例は75歳の女性で，66歳時に胃GISTで幽門保存胃切除術施行し経過観察中であった．経過観察CTで十二指腸水平脚に径20mmの腫瘤を認め，ボーリング生検でGISTと診断し，十二指腸楔状切除術を施行した．胃と十二指腸標本の免疫組 …
NAID 130005095211